{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:35:54Z","timestamp":1793730954327,"version":"4.6.1"},"reference-count":139,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.clinbiochem.2025.110929","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T18:20:00Z","timestamp":1745086800000},"page":"110929","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Lp(a): A Clinical Review"],"prefix":"10.1016","volume":"137","author":[{"given":"Khalil","family":"Anchouche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Baass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Thanassoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"39","key":"10.1016\/j.clinbiochem.2025.110929_b0005","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur. Heart J."},{"issue":"8","key":"10.1016\/j.clinbiochem.2025.110929_b0010","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1194\/jlr.R067314","article-title":"Structure, function, and genetics of lipoprotein (a)","volume":"57","author":"Schmidt","year":"2016","journal-title":"J. Lipid Res."},{"issue":"3","key":"10.1016\/j.clinbiochem.2025.110929_b0015","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","article-title":"Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association","volume":"13","author":"Wilson","year":"2019","journal-title":"J. Clin. Lipidol."},{"issue":"2","key":"10.1016\/j.clinbiochem.2025.110929_b0020","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/MOL.0000000000000392","article-title":"Lipoprotein(a): new insights from modern genomics","volume":"28","author":"Afshar","year":"2017","journal-title":"Curr. Opin. Lipidol."},{"issue":"6","key":"10.1016\/j.clinbiochem.2025.110929_b0025","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.clinbiochem.2025.110929_b0030","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.119.002862","article-title":"Genome-wide association study of peripheral artery disease","volume":"14","author":"van Zuydam","year":"2021","journal-title":"Circ. Genom. Precis. Med."},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.110929_b0035","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","article-title":"Elevated lipoprotein(a) and risk of ischemic stroke","volume":"74","author":"Langsted","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.110929_b0040","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jchf.2015.08.006","article-title":"Elevated lipoprotein(a) levels, LPA risk genotypes, and increased risk of heart failure in the general population","volume":"4","author":"Kamstrup","year":"2016","journal-title":"JACC Heart Fail"},{"issue":"16","key":"10.1016\/j.clinbiochem.2025.110929_b0045","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1161\/CIRCULATIONAHA.109.913673","article-title":"Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies","volume":"121","author":"Kenet","year":"2010","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.clinbiochem.2025.110929_b0050","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1161\/ATVBAHA.116.308011","article-title":"Prevalence of elevated Lp(a) mass levels and patient thresholds in 532 359 patients in the United States","volume":"36","author":"Varvel","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.110929_b0055","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"6","key":"10.1016\/j.clinbiochem.2025.110929_b0060","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/MOL.0000000000000856","article-title":"Recent lipoprotein(a) trials","volume":"33","author":"Wei","year":"2022","journal-title":"Curr. Opin. Lipidol."},{"issue":"6144","key":"10.1016\/j.clinbiochem.2025.110929_b0065","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/330132a0","article-title":"cDNA sequence of human apolipoprotein(a) is homologous to plasminogen","volume":"330","author":"McLean","year":"1987","journal-title":"Nature"},{"issue":"22","key":"10.1016\/j.clinbiochem.2025.110929_b0070","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"J. Am. Med. Assoc."},{"issue":"3","key":"10.1016\/j.clinbiochem.2025.110929_b0075","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.tips.2019.01.004","article-title":"New frontiers in Lp(a)-targeted therapies","volume":"40","author":"Borrelli","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"issue":"32","key":"10.1016\/j.clinbiochem.2025.110929_b0080","doi-asserted-by":"crossref","first-page":"9919","DOI":"10.1021\/bi060283t","article-title":"Catalysis of covalent Lp(a) assembly: evidence for an extracellular enzyme activity that enhances disulfide bond formation","volume":"45","author":"Becker","year":"2006","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.110929_b0085","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/joim.12981","article-title":"Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities","volume":"287","author":"Vuorio","year":"2020","journal-title":"J. Intern. Med."},{"issue":"7","key":"10.1016\/j.clinbiochem.2025.110929_b0090","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1161\/CIRCRESAHA.116.310272","article-title":"Recycling of apolipoprotein(a) after PlgRKT-mediated endocytosis of lipoprotein(a)","volume":"120","author":"Sharma","year":"2017","journal-title":"Circ. Res."},{"issue":"4","key":"10.1016\/j.clinbiochem.2025.110929_b0095","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1194\/jlr.R083626","article-title":"The role of lipoprotein (a) in chronic kidney disease","volume":"59","author":"Hopewell","year":"2018","journal-title":"J. Lipid Res."},{"issue":"12","key":"10.1016\/j.clinbiochem.2025.110929_b0100","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jamacardio.2019.3780","article-title":"Apolipoprotein B particles and cardiovascular disease: a narrative review","volume":"4","author":"Sniderman","year":"2019","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.clinbiochem.2025.110929_b0105","doi-asserted-by":"crossref","first-page":"134","DOI":"10.12688\/f1000research.9845.1","article-title":"Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease","volume":"6","author":"Shapiro","year":"2017","journal-title":"F1000Res"},{"issue":"3","key":"10.1016\/j.clinbiochem.2025.110929_b0110","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jacc.2023.10.039","article-title":"Lipoprotein(a) is markedly more atherogenic than LDL: an apolipoprotein B-based genetic analysis","volume":"83","author":"Bj\u00f6rnson","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.clinbiochem.2025.110929_b0115","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.atherosclerosis.2022.04.004","article-title":"Lipoprotein(a): an underestimated inflammatory mastermind","volume":"349","author":"Dzobo","year":"2022","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.clinbiochem.2025.110929_b0120","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans","volume":"134","author":"van der Valk","year":"2016","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.clinbiochem.2025.110929_b0125","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1093\/eurheartj\/ehaa171","article-title":"Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a)","volume":"41","author":"Stiekema","year":"2020","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.clinbiochem.2025.110929_b0130","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1161\/01.ATV.20.4.1137","article-title":"Major reduction in plasma Lp(a) levels during sepsis and burns","volume":"20","author":"Mooser","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"3","key":"10.1016\/j.clinbiochem.2025.110929_b0135","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/bjs.5273","article-title":"Lipoprotein(a), lipids and proinflammatory cytokines in patients undergoing major abdominal surgery","volume":"93","author":"Chimienti","year":"2006","journal-title":"Br. J. Surg."},{"issue":"2\u20133","key":"10.1016\/j.clinbiochem.2025.110929_b0140","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0021-9150(89)90218-9","article-title":"Transient changes of serum lipoprotein(a) as an acute phase protein","volume":"78","author":"Maeda","year":"1989","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.clinbiochem.2025.110929_b0145","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1161\/01.RES.78.4.615","article-title":"Specific accumulation of lipoprotein(a) in balloon-injured rabbit aorta in vivo","volume":"78","author":"Nielsen","year":"1996","journal-title":"Circ. Res."},{"issue":"11","key":"10.1016\/j.clinbiochem.2025.110929_b0150","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1161\/CIRCRESAHA.110.234138","article-title":"Calcific aortic valve stenosis: methods, models, and mechanisms","volume":"108","author":"Miller","year":"2011","journal-title":"Circ. Res."},{"issue":"5","key":"10.1016\/j.clinbiochem.2025.110929_b0155","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cmet.2010.09.010","article-title":"Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress","volume":"12","author":"Seimon","year":"2010","journal-title":"Cell Metab."},{"issue":"2","key":"10.1016\/j.clinbiochem.2025.110929_b0160","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/BF00308315","article-title":"Colocalization of cholesterol and hydroxyapatite in human atherosclerotic lesions","volume":"52","author":"Hirsch","year":"1993","journal-title":"Calcif. Tissue Int."},{"issue":"8","key":"10.1016\/j.clinbiochem.2025.110929_b0165","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/CIRCULATIONAHA.115.016757","article-title":"Autotaxin derived from lipoprotein(a) and valve interstitial cells promotes inflammation and mineralization of the aortic valve","volume":"132","author":"Bouchareb","year":"2015","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.clinbiochem.2025.110929_b0170","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1194\/jlr.R061648","article-title":"Lipoprotein (a) measurements for clinical application","volume":"57","author":"Marcovina","year":"2016","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.clinbiochem.2025.110929_b0175","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.atherosclerosis.2022.04.008","article-title":"Lipoprotein(a) measurement issues: are we making a mountain out of a molehill?","volume":"349","author":"Kronenberg","year":"2022","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.110929_b0180","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jamacardio.2023.4115","article-title":"Mendelian randomization as a tool for cardiovascular research: a review","volume":"9","author":"Levin","year":"2024","journal-title":"JAMA Cardiol."},{"issue":"6","key":"10.1016\/j.clinbiochem.2025.110929_b0185","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.clinbiochem.2025.110929_b0190","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"25","key":"10.1016\/j.clinbiochem.2025.110929_b0195","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1016\/j.jacc.2016.10.033","article-title":"Phenotypic characterization of genetically lowered human lipoprotein(a) levels","volume":"68","author":"Emdin","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"issue":"24","key":"10.1016\/j.clinbiochem.2025.110929_b0200","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.jacc.2023.10.009","article-title":"Lipoprotein(a) and risks of peripheral artery disease, abdominal aortic aneurysm, and major adverse limb events","volume":"82","author":"Thomas","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.clinbiochem.2025.110929_b0205","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCGENETICS.113.000400","article-title":"Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort","volume":"7","author":"Arsenault","year":"2014","journal-title":"Circ. Cardiovasc. Genet."},{"issue":"7","key":"10.1016\/j.clinbiochem.2025.110929_b0210","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol."},{"issue":"26","key":"10.1016\/j.clinbiochem.2025.110929_b0215","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.110929_b0220","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/ng.2480","article-title":"Large-scale association analysis identifies new risk loci for coronary artery disease","volume":"45","author":"Deloukas","year":"2013","journal-title":"Nat. Genet."},{"issue":"4","key":"10.1016\/j.clinbiochem.2025.110929_b0225","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"J. Am. Med. Assoc."},{"issue":"6","key":"10.1016\/j.clinbiochem.2025.110929_b0230","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jamacardio.2019.1041","article-title":"Estimation of the required lipoprotein(a)-lowering therapeutic effect size for reduction in coronary heart disease outcomes: a Mendelian randomization analysis","volume":"4","author":"Lamina","year":"2019","journal-title":"JAMA Cardiol."},{"issue":"1\u20132","key":"10.1016\/j.clinbiochem.2025.110929_b0235","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0021-9150(81)90103-9","article-title":"Lipoprotein Lp(a) and the risk for myocardial infarction","volume":"38","author":"Kostner","year":"1981","journal-title":"Atherosclerosis"},{"issue":"18","key":"10.1016\/j.clinbiochem.2025.110929_b0240","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1001\/jama.1986.03380180102027","article-title":"Lp(a) lipoprotein as a risk factor for myocardial infarction","volume":"256","author":"Rhoads","year":"1986","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.clinbiochem.2025.110929_b0245","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2022.04.013","article-title":"Mendelian Randomization: principles and its usage in Lp(a) research","volume":"349","author":"Lamina","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinbiochem.2025.110929_b0250","article-title":"Mendelian randomization as a tool for cardiovascular research: a review","author":"Levin","year":"2023","journal-title":"JAMA Cardiol."},{"issue":"2","key":"10.1016\/j.clinbiochem.2025.110929_b0255","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1161\/01.CIR.90.2.844","article-title":"Characterization of the early lesion of \u2018degenerative\u2019 valvular aortic stenosis. Histological and immunohistochemical studies","volume":"90","author":"Otto","year":"1994","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.clinbiochem.2025.110929_b0260","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1161\/01.ATV.16.4.523","article-title":"Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis","volume":"16","author":"O'Brien","year":"1996","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"12","key":"10.1016\/j.clinbiochem.2025.110929_b0265","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S0002-9149(99)80263-X","article-title":"Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study)","volume":"76","author":"Gotoh","year":"1995","journal-title":"Am. J. Cardiol."},{"issue":"3","key":"10.1016\/j.clinbiochem.2025.110929_b0270","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0735-1097(96)00563-3","article-title":"Clinical factors associated with calcific aortic valve disease. cardiovascular health study","volume":"29","author":"Stewart","year":"1997","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.clinbiochem.2025.110929_b0275","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0195-668X(02)00385-8","article-title":"Lipoprotein(a), Chlamydia pneumoniae, leptin and tissue plasminogen activator as risk markers for valvular aortic stenosis","volume":"24","author":"Glader","year":"2003","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.clinbiochem.2025.110929_b0280","first-page":"387","article-title":"Effects of serum levels of novel atherosclerotic risk factors on aortic valve calcification","volume":"16","author":"Bozbas","year":"2007","journal-title":"J. Heart Valve Dis."},{"issue":"6","key":"10.1016\/j.clinbiochem.2025.110929_b0285","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1194\/jlr.R051870","article-title":"Lipoprotein (a) in calcific aortic valve disease: from genomics to novel drug target for aortic stenosis","volume":"57","author":"Thanassoulis","year":"2016","journal-title":"J. Lipid Res."},{"issue":"2","key":"10.1016\/j.clinbiochem.2025.110929_b0290","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcmg.2022.09.007","article-title":"Lipoprotein(a) and aortic valve calcification: the multi-ethnic study of atherosclerosis","volume":"16","author":"Bhatia","year":"2023","journal-title":"J. Am. Coll. Cardiol. Img."},{"issue":"24","key":"10.1016\/j.clinbiochem.2025.110929_b0295","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1161\/CIR.0000000000001106","article-title":"2022 ACC\/AHA guideline for the diagnosis and management of aortic disease: a report of the American heart association\/American college of cardiology joint committee on clinical practice guidelines","volume":"146","author":"Isselbacher","year":"2022","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.clinbiochem.2025.110929_b0300","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2019.01.070","article-title":"Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis","volume":"73","author":"Zheng","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"11","key":"10.1016\/j.clinbiochem.2025.110929_b0305","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jacc.2015.07.020","article-title":"Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis","volume":"66","author":"Capoulade","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.clinbiochem.2025.110929_b0310","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/CIRCULATIONAHA.109.900027","article-title":"Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial","volume":"121","author":"Chan","year":"2010","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.clinbiochem.2025.110929_b0315","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1056\/NEJMoa043876","article-title":"A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis","volume":"352","author":"Cowell","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.clinbiochem.2025.110929_b0320","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis","volume":"359","author":"Rosseb\u00f8","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.clinbiochem.2025.110929_b0325","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.amjcard.2008.04.060","article-title":"Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg)","volume":"102","author":"Dichtl","year":"2008","journal-title":"Am. J. Cardiol."},{"issue":"5","key":"10.1016\/j.clinbiochem.2025.110929_b0330","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1161\/ATVBAHA.115.306683","article-title":"Lipoprotein(a) levels are associated with subclinical calcific aortic valve disease in white and black individuals: the multi-ethnic study of atherosclerosis","volume":"36","author":"Cao","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"5","key":"10.1016\/j.clinbiochem.2025.110929_b0335","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.amjcard.2009.10.071","article-title":"Incidence and progression of aortic valve calcium in the multi-ethnic study of atherosclerosis (MESA)","volume":"105","author":"Owens","year":"2010","journal-title":"Am. J. Cardiol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.110929_b0340","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1148\/radiol.2021202630","article-title":"Association between aortic valve calcification progression and coronary atherosclerotic plaque volume progression in the PARADIGM registry","volume":"300","author":"Lee","year":"2021","journal-title":"Radiology"},{"issue":"17","key":"10.1016\/j.clinbiochem.2025.110929_b0345","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1136\/heartjnl-2021-319044","article-title":"Lipoprotein(a) is robustly associated with aortic valve calcium","volume":"107","author":"Kaiser","year":"2021","journal-title":"Heart"},{"issue":"17","key":"10.1016\/j.clinbiochem.2025.110929_b0350","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jacc.2010.06.030","article-title":"Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study","volume":"56","author":"Erbel","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.clinbiochem.2025.110929_b0355","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2024.1882","article-title":"Lipoprotein(a) and calcific aortic valve stenosis progression: a systematic review and meta-analysis","author":"Arsenault","year":"2024","journal-title":"JAMA Cardiol."},{"issue":"12","key":"10.1016\/j.clinbiochem.2025.110929_b0360","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1161\/ATVBAHA.112.255521","article-title":"Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study","volume":"32","author":"Gurdasani","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"3","key":"10.1016\/j.clinbiochem.2025.110929_b0365","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000319067","article-title":"Relative contribution of lipids and apolipoproteins to incident coronary heart disease and ischemic stroke: the PRIME Study","volume":"30","author":"Canou\u00ef-Poitrine","year":"2010","journal-title":"Cerebrovasc. Dis."},{"issue":"6","key":"10.1016\/j.clinbiochem.2025.110929_b0370","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1161\/STROKEAHA.106.480657","article-title":"Lipoprotein (a) and stroke: a meta-analysis of observational studies","volume":"38","author":"Smolders","year":"2007","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.110929_b0375","doi-asserted-by":"crossref","first-page":"15660","DOI":"10.1038\/s41598-021-95141-0","article-title":"Lipoprotein (a) level as a risk factor for stroke and its subtype: a systematic review and meta-analysis","volume":"11","author":"Kumar","year":"2021","journal-title":"Sci. Rep."},{"issue":"22","key":"10.1016\/j.clinbiochem.2025.110929_b0380","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1093\/eurheartj\/ehab081","article-title":"Lipoprotein(a) is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: results from the BIOSIGNAL study","volume":"42","author":"Arnold","year":"2021","journal-title":"Eur. Heart J."},{"issue":"22","key":"10.1016\/j.clinbiochem.2025.110929_b0385","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1093\/eurheartj\/ehab251","article-title":"Elevated lipoprotein(a) and the risk of stroke in children, young adults, and the elderly","volume":"42","author":"Tsimikas","year":"2021","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.clinbiochem.2025.110929_b0390","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1161\/ATVBAHA.118.311857","article-title":"Lipoprotein(a) and risk of ischemic stroke in the REGARDS study","volume":"39","author":"Arora","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"10","key":"10.1016\/j.clinbiochem.2025.110929_b0395","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1161\/ATVBAHA.118.311220","article-title":"Lp(a) [Lipoprotein(a)]-related risk of heart failure is evident in whites but not in other racial\/ethnic groups","volume":"38","author":"Steffen","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.clinbiochem.2025.110929_b0400","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.atherosclerosis.2017.05.014","article-title":"The association of lipoprotein(a) with incident heart failure hospitalization: atherosclerosis risk in communities study","volume":"262","author":"Agarwala","year":"2017","journal-title":"Atherosclerosis"},{"issue":"24","key":"10.1016\/j.clinbiochem.2025.110929_b0405","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/j.jacc.2023.10.016","article-title":"Association of lipoprotein(a) levels with myocardial fibrosis in the multi-ethnic study of atherosclerosis","volume":"82","author":"Chehab","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"10.1016\/j.clinbiochem.2025.110929_b0410","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.45720","article-title":"Association of lipoprotein(a) levels with incidence of major adverse limb events","volume":"5","author":"Gu\u00e9don","year":"2022","journal-title":"JAMA Netw. Open"},{"issue":"Suppl 6","key":"10.1016\/j.clinbiochem.2025.110929_b0415","doi-asserted-by":"crossref","first-page":"S242","DOI":"10.21037\/atm.2019.08.77","article-title":"Role of lipoprotein (a) in peripheral arterial disease","volume":"7","author":"Kosmas","year":"2019","journal-title":"Ann. Transl. Med."},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.110929_b0420","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American heart association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"2","key":"10.1016\/j.clinbiochem.2025.110929_b0425","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/CIRCULATIONAHA.111.045120","article-title":"Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) study","volume":"125","author":"Virani","year":"2012","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.clinbiochem.2025.110929_b0430","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.118.034311","article-title":"Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups","volume":"139","author":"Par\u00e9","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.clinbiochem.2025.110929_b0435","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.atherosclerosis.2022.04.006","article-title":"Non-genetic influences on lipoprotein(a) concentrations","volume":"349","author":"Enkhmaa","year":"2022","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.clinbiochem.2025.110929_b0440","doi-asserted-by":"crossref","DOI":"10.3390\/nu12072024","article-title":"Diet and Lp(a): does dietary change modify residual cardiovascular risk conferred by Lp(a)?","volume":"12","author":"Enkhmaa","year":"2020","journal-title":"Nutrients"},{"issue":"Pt 2","key":"10.1016\/j.clinbiochem.2025.110929_b0445","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/000456329503200208","article-title":"Long-term physical exercise and lipoprotein(a) levels in a previously sedentary male and female population","volume":"32","author":"Ponjee","year":"1995","journal-title":"Ann. Clin. Biochem."},{"issue":"5","key":"10.1016\/j.clinbiochem.2025.110929_b0450","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S0026-0495(00)80041-4","article-title":"Effect of physical exercise on lipoprotein(a) and low-density lipoprotein modifications in type 1 and type 2 diabetic patients","volume":"49","author":"Rigla","year":"2000","journal-title":"Metabolism"},{"issue":"11","key":"10.1016\/j.clinbiochem.2025.110929_b0455","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/aje\/kwp043","article-title":"Lipid changes during the menopause transition in relation to age and weight: the study of women\u2019s health across the nation","volume":"169","author":"Derby","year":"2009","journal-title":"Am. J. Epidemiol."},{"issue":"12","key":"10.1016\/j.clinbiochem.2025.110929_b0460","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa672","article-title":"Treatment of thyroid dysfunction and serum lipids: a systematic review and meta-analysis","volume":"105","author":"Kotwal","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.clinbiochem.2025.110929_b0465","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s10157-013-0875-8","article-title":"Causes and consequences of lipoprotein(a) abnormalities in kidney disease","volume":"18","author":"Kronenberg","year":"2014","journal-title":"Clin. Exp. Nephrol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.110929_b0470","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1681\/ASN.V61110","article-title":"Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis","volume":"6","author":"Kronenberg","year":"1995","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.clinbiochem.2025.110929_b0475","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-119-4-199308150-00002","article-title":"Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome","volume":"119","author":"Wanner","year":"1993","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.clinbiochem.2025.110929_b0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.117437","article-title":"Elevated lipoprotein(a) increases risk of subsequent major adverse cardiovascular events (MACE) and coronary revascularisation in incident ASCVD patients: a cohort study from the UK Biobank","volume":"389","author":"Welsh","year":"2024","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.clinbiochem.2025.110929_b0485","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jacc.2012.12.023","article-title":"Extreme lipoprotein(a) levels and improved cardiovascular risk prediction","volume":"61","author":"Kamstrup","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"10.1016\/j.clinbiochem.2025.110929_b0490","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jacc.2014.03.061","article-title":"Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck study","volume":"64","author":"Willeit","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"18","key":"10.1016\/j.clinbiochem.2025.110929_b0495","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1093\/eurjpc\/zwaa063","article-title":"Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions","volume":"28","author":"Welsh","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.clinbiochem.2025.110929_b0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.117217","article-title":"Lipoprotein(a) and the pooled cohort equations for ASCVD risk prediction: the Multi-Ethnic study of atherosclerosis","volume":"381","author":"Bhatia","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinbiochem.2025.110929_b0505","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.atherosclerosis.2016.11.010","article-title":"Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: the EPIC-Norfolk prospective population study","volume":"256","author":"Perrot","year":"2017","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.clinbiochem.2025.110929_b0510","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.clinbiochem.2025.110929_b0515","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014711","article-title":"Risks of incident cardiovascular disease associated with concomitant elevations in lipoprotein(a) and low-density lipoprotein cholesterol-the framingham heart study","volume":"9","author":"Afshar","year":"2020","journal-title":"J. Am. Heart Assoc."},{"issue":"9","key":"10.1016\/j.clinbiochem.2025.110929_b0520","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1161\/ATVBAHA.115.305835","article-title":"Effects of extended-release nicotinic acid on apolipoprotein (a) kinetics in hypertriglyceridemic patients","volume":"35","author":"Croyal","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"24","key":"10.1016\/j.clinbiochem.2025.110929_b0525","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.clinbiochem.2025.110929_b0530","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMe1812000","article-title":"Should aspirin be used for primary prevention in the post-statin era?","volume":"379","author":"Ridker","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.clinbiochem.2025.110929_b0535","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jacc.2022.07.027","article-title":"Aspirin for primary prevention of cardiovascular events in relation to lipoprotein(a) genotypes","volume":"80","author":"Lacaze","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"issue":"16","key":"10.1016\/j.clinbiochem.2025.110929_b0540","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1803955","article-title":"Effect of aspirin on all-cause mortality in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.clinbiochem.2025.110929_b0545","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa050613","article-title":"A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women","volume":"352","author":"Ridker","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.clinbiochem.2025.110929_b0550","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.atherosclerosis.2008.07.019","article-title":"Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy","volume":"203","author":"Chasman","year":"2009","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.clinbiochem.2025.110929_b0555","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.033562","article-title":"Aspirin and cardiovascular risk in individuals with elevated lipoprotein(a): the multi-ethnic study of atherosclerosis","volume":"13","author":"Bhatia","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.clinbiochem.2025.110929_b0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100674","article-title":"Aspirin use for primary prevention among US adults with and without elevated Lipoprotein(a)","volume":"18","author":"Razavi","year":"2024","journal-title":"Am. J. Prev. Cardiol."},{"issue":"9","key":"10.1016\/j.clinbiochem.2025.110929_b0565","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/eurheartj\/ehs023","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial","volume":"33","author":"Visser","year":"2012","journal-title":"Eur. Heart J."},{"issue":"23","key":"10.1016\/j.clinbiochem.2025.110929_b0570","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jacc.2013.07.081","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Thomas","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9860","key":"10.1016\/j.clinbiochem.2025.110929_b0575","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.clinbiochem.2025.110929_b0580","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCULATIONAHA.113.001292","article-title":"Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia","volume":"129","author":"Rader","year":"2014","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.clinbiochem.2025.110929_b0585","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41569-018-0107-8","article-title":"PCSK9 inhibitors: clinical evidence and implementation","volume":"16","author":"Sabatine","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"issue":"18","key":"10.1016\/j.clinbiochem.2025.110929_b0590","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.clinbiochem.2025.110929_b0595","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O\u2019Donoghue","year":"2019","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.clinbiochem.2025.110929_b0600","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.clinbiochem.2025.110929_b0605","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"23","key":"10.1016\/j.clinbiochem.2025.110929_b0610","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.016318","article-title":"Low-density lipoprotein cholesterol corrected for lipoprotein(a) cholesterol, risk thresholds, and cardiovascular events","volume":"9","author":"Willeit","year":"2020","journal-title":"J. Am. Heart Assoc."},{"issue":"7","key":"10.1016\/j.clinbiochem.2025.110929_b0615","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11883-019-0787-5","article-title":"Current role of lipoprotein apheresis","volume":"21","author":"Thompson","year":"2019","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.clinbiochem.2025.110929_b0620","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.atherosclerosissup.2017.05.006","article-title":"Current insights into the German lipoprotein apheresis registry (GLAR) - almost 5 years on","volume":"30","author":"Schettler","year":"2017","journal-title":"Atheroscler. Suppl."},{"issue":"5","key":"10.1016\/j.clinbiochem.2025.110929_b0625","doi-asserted-by":"crossref","first-page":"e738","DOI":"10.1016\/j.jacl.2024.04.134","article-title":"Long-term lipoprotein apheresis reduces cardiovascular events in high-risk patients with isolated lipoprotein(a) elevation","volume":"18","author":"Schumann","year":"2024","journal-title":"J. Clin. Lipidol."},{"issue":"7","key":"10.1016\/j.clinbiochem.2025.110929_b0630","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41587-022-01396-x","article-title":"RNA drugs lower lipoprotein(a) and genetically driven cholesterol","volume":"40","author":"Sheridan","year":"2022","journal-title":"Nat. Biotechnol."},{"issue":"10","key":"10.1016\/j.clinbiochem.2025.110929_b0635","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10002","key":"10.1016\/j.clinbiochem.2025.110929_b0640","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study","volume":"386","author":"Tsimikas","year":"2015","journal-title":"Lancet"},{"issue":"10057","key":"10.1016\/j.clinbiochem.2025.110929_b0645","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.clinbiochem.2025.110929_b0650","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.110929_b0655","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","article-title":"Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)","volume":"28","author":"Koren","year":"2022","journal-title":"Nat. Med."},{"issue":"20","key":"10.1016\/j.clinbiochem.2025.110929_b0660","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O'Donoghue","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.clinbiochem.2025.110929_b0665","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2022.5050","article-title":"Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels","volume":"327","author":"Nissen","year":"2022","journal-title":"J. Am. Med. Assoc."},{"issue":"21","key":"10.1016\/j.clinbiochem.2025.110929_b0670","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1001\/jama.2023.21835","article-title":"Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): a randomized dose-ascending clinical trial","volume":"330","author":"Nissen","year":"2023","journal-title":"J. Am. Med. Assoc."},{"issue":"11","key":"10.1016\/j.clinbiochem.2025.110929_b0675","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1001\/jama.2023.16503","article-title":"Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation: a randomized clinical trial","volume":"330","author":"Nicholls","year":"2023","journal-title":"J. Am. Med. Assoc."},{"issue":"8","key":"10.1016\/j.clinbiochem.2025.110929_b0680","first-page":"1129","article-title":"2021 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can. J. Cardiol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.110929_b0685","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"issue":"25","key":"10.1016\/j.clinbiochem.2025.110929_b0690","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.clinbiochem.2025.110929_b0695","unstructured":"M.L. Koschinsky, D.E. Soffer, M.B. Boffa. What\u2019s next for lipoprotein(a)? A national lipid association report from an expert panel discussion. J. Clin. Lipidol."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000991202500058X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000991202500058X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T18:51:58Z","timestamp":1763664718000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000991202500058X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":139,"alternative-id":["S000991202500058X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2025.110929","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lp(a): A Clinical Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2025.110929","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110929"}}